Sector
PharmaceuticalsOpen
₹351.2Prev. Close
₹351.65Turnover(Lac.)
₹82.31Day's High
₹354Day's Low
₹34752 Week's High
₹504.2552 Week's Low
₹298.8Book Value
₹60.08Face Value
₹1Mkt Cap (₹ Cr.)
3,501.19P/E
50.02EPS
6.97Divi. Yield
0.03Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 10.03 | 9.69 | 9.69 | 9.69 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 522.53 | 338.11 | 259.42 | 163.74 |
Net Worth | 532.56 | 347.8 | 269.11 | 173.43 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Revenue | 779.15 | 487.69 | 357.75 | 300.96 |
yoy growth (%) | 59.76 | 36.32 | 18.86 | 22.58 |
Raw materials | -411.96 | -250.29 | -177.47 | -142.22 |
As % of sales | 52.87 | 51.32 | 49.6 | 47.25 |
Employee costs | -85.61 | -66.21 | -51.57 | -44.46 |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Profit before tax | 126.83 | 57.71 | 30.33 | 27.95 |
Depreciation | -17.13 | -16.3 | -8.35 | -4.3 |
Tax paid | -30.99 | -13.47 | -7.47 | -13.51 |
Working capital | 30.22 | -13.96 | 33.14 | 35.94 |
Other operating items |
Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 59.76 | 36.32 | 18.86 | 22.58 |
Op profit growth | 73.63 | 88.23 | 16.83 | 66.26 |
EBIT growth | 84.57 | 65.73 | 16.98 | 77.7 |
Net profit growth | 116.67 | 93.51 | 42.66 | 77.6 |
Particulars (Rupees in Crores.) | Mar-2025 | Mar-2024 |
---|---|---|
Gross Sales | 819.81 | 806.67 |
Excise Duty | 0 | 0 |
Net Sales | 819.81 | 806.67 |
Other Operating Income | 0 | 0 |
Other Income | 3.63 | 2.18 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,669.8 | 93.52 | 4,00,520.99 | 2,000.46 | 0.96 | 7,107.14 | 101.44 |
Divis Laboratories Ltd DIVISLAB | 6,616 | 79.48 | 1,75,574.28 | 667 | 0.45 | 2,536 | 561.08 |
Cipla Ltd CIPLA | 1,513.8 | 25.39 | 1,22,186 | 1,485.4 | 1.06 | 4,254.47 | 397.41 |
Dr Reddys Laboratories Ltd DRREDDY | 1,321.5 | 20.61 | 1,10,263.53 | 1,200.7 | 0.61 | 5,546.3 | 345.76 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,222.5 | 57.29 | 1,09,167.44 | 474 | 0.99 | 2,385 | 224.33 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Managing Director
Jayesh P Choksi
Whole Time Director & CEO
Pranav J Choksi
Whole-time Director
Pankaj Gandhi
Company Sec. & Compli. Officer
Ami Naresh Shah
Non-Exec. & Independent Dir.
Shrirang V Vadiya
Non-Exec & Non-Independent Dir
Balram Singh
Non-Exec. & Independent Dir.
Rabi Narayan Sahoo
Non-Exec. & Independent Dir.
Anusanjiv Aurora
Whole-time Director
Dilip Ghosh
Non-Exec. & Independent Dir.
Kamal Kishore Seth
Additional Director
Akshya Kumar Mahapatra
Shop-37 1st Flr Kamala Bhavan,
Swami Nityanand Road Andheri(E,
Maharashtra - 400069
Tel: 91-022-66919187/67261007/66919189
Website: http://www.gufic.com
Email: [email protected]; mgr_legal@guficbi
C-13 Pannalal Silk,
Mills Cmpd LBS Marg, Bhandup West,
Mumbai - 400 078
Tel: 91-022-25963838
Website: www.linkintime.co.in
Summary
Gufic Biosciences Limited is a prominent global pharmaceutical enterprise dedicated to delivering a broad spectrum of pharmaceutical services to its clients. Renowned for its extensive range of pharm...
Read More
Reports by Gufic BioSciences Ltd
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.